After signing up, you'll start to receive regular news updates from us.
Stem Cell Innovations Collaborate with MEEI
Complete the form below to unlock access to ALL audio articles.
Stem Cell Innovations, Inc. has announced that the Company will collaborate with Massachusetts Eye and Ear Infirmary (MEEI).
Under the material transfer agreement, MEEI will evaluate PluriCells™ for their capacity to form the human tissues implicated in hearing loss.
In return SCI will receive a nonexclusive license to intellectual property generated using the PluriCells.
"This collaboration with MEEI is another example of our strategy to work with top research groups in the world to accelerate human stem cell research," said Stem Cell Innovations CEO Dr. James Kelly.
"As our PluriCells do not fall under the Presidential ban, there is a lot of interest from the academic world to get access to our human pluripotent stem cell platform."
"Exploring the potential of PluriCells for our research is really exciting," said Dr. Albert Edge.
"Until now, our research was hampered by a lack of good quality human stem cells."
Stem Cell Innovations recently disclosed it has produced multiple lines of human pluripotent stem cells.
These PluriCell lines can be cultured in tissue culture plates without the use of feeder layers and can be differentiated into multiple cell-types, having the potential to aid in drug discovery and development.
PluriCells are a type of pluripotent stem cell isolated from fetal tissue that have the ability to become all cell types of the body.
Because they are developed from fetal germ cells, not viable embryos, they are eligible to be used in any NIH funded laboratory.
